Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities

類似資料

• International Staging System and Metaphase Cytogenetic Abnormalities in the Era of Gene Expression Profiling Data in Multiple Myeloma Treated with Total Therapy 2 and 3 Protocols
  著者:: Waheed, Sarah, 等
  出版事項: (2010)
• Adverse metaphase cytogenetics can be overcome by adding bortezomib and thalidomide to fractionated melphalan transplants
  著者:: Jethava, Yogesh S, 等
  出版事項: (2016)
• Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols
  著者:: Hoering, Antje, 等
  出版事項: (2009)
• Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2
  著者:: Pineda-Roman, Mauricio, 等
  出版事項: (2008)
• Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy
  著者:: van Rhee, Frits, 等
  出版事項: (2010)